Patients who were given RP103 showed a slower progression of total motor control, or a drop in the loss of motion control, than patients given a placebo treatment, Raptor said Thursday.
Slower progression was seen across all of the sub-measurements, including eye and hand movements, balance and gait, as well as maximal dystonia and maximal chore, Raptor added.
Adverse reactions were similar in patients given the RP103 treatment versus the placebo. Five patients treated with RP103 experienced serious side effects compared with four patients treated with the placebo.
"We are very encouraged by these trial results and we believe that the significant slowdown of loss of muscle control in these early stage patients indicates that RP103 is potentially effective at slowing the progression of Huntington's disease," said Christophe Verny, lead investigator for the clinical trial.
with a quick read it looks good . And in areas that pbt2 did not do as well in. Longer time frame though. I believe this company is from the ashes of torrey pines that Dr. Tanzi was involved with years ago.